| Basics |
Altimmune, Inc.
Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases.
|
| IPO Date: |
May 22, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$339.03M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.31 | 4.17%
|
| Avg Daily Range (30 D): |
$0.23 | 4.72%
|
| Avg Daily Range (90 D): |
$0.19 | 3.75%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.81M |
| Avg Daily Volume (30 D): |
8.01M |
| Avg Daily Volume (90 D): |
4.27M |
| Trade Size |
| Avg Trade Size (Sh.): |
158 |
| Avg Trade Size (Sh.) (30 D): |
194 |
| Avg Trade Size (Sh.) (90 D): |
169 |
| Institutional Trades |
| Total Inst.Trades: |
1,437 |
| Avg Inst. Trade: |
$1.73M |
| Avg Inst. Trade (30 D): |
$1.53M |
| Avg Inst. Trade (90 D): |
$1.21M |
| Avg Inst. Trade Volume: |
.19M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.99M |
| Avg Closing Trade (30 D): |
$1.58M |
| Avg Closing Trade (90 D): |
$1.18M |
| Avg Closing Volume: |
223.54K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.26
|
$-.32
|
|
Diluted EPS
|
|
$-.26
|
$-.32
|
|
Revenue
|
$
|
$ .01M
|
$ .01M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -19.58M
|
$ -22.85M
|
|
Operating Income / Loss
|
$
|
$ -21.82M
|
$ -24.77M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 12.18M
|
$ -25.65M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Sep 14, 2018:
1:30
|
|
May 05, 2017:
1:10
|
|
May 04, 2017:
1:10
|
|
Jul 25, 2007:
1:50
|
|
|
|
